Telix Pharmaceuticals
Telix Pharmaceuticals' revenue rose 55.6% to $804 million in fiscal 2025. Its operating margin was 3.7%, down from 10.7% a year earlier. Free cash flow was −$43 million, against $18 million a year earlier. The diluted share count fell 2.1%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Income statement
From fiscal 2023 to 2024, earnings per share grew 900.0% a year and net income 702.4% a year, as new shares raised the share count by 7% and diluted each share's earnings. Telix Pharmaceuticals then lost money in fiscal 2025.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Cash and short-term investments | 79 | 84 | 440 | 142 |
| Debt incl. finance leases | — | 7 | 354 | 405 |
| Net debt (negative means net cash) | — | −78 | −86 | 263 |
| Net debt to EBITDA | — | −5.0x | −1.4x | 5.1x |
| Debt to equity | — | 0.1x | 1.0x | 1.0x |
| Interest coverage | — | 113.5x | 862.1x | 164.5x |
| Current ratio | — | 1.4x | 2.8x | 1.4x |
| Quick ratio | — | 1.3x | 2.7x | 1.3x |
Cash flow
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | 2 of 9 |
| Rule of 40 | — | 58.7% | 50.3% |
| Altman Z'' | −0.20 | 3.04 | 0.88 |
| Accruals ratio | — | 1.0% | 1.0% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | — | Pass | Fail |
| Cash from operations is positive | Pass | Pass | Fail |
| Return on assets rose | — | — | Fail |
| Cash from operations exceeds net income | Pass | Fail | Fail |
| Debt fell relative to assets | — | — | Pass |
| Current ratio rose | — | Pass | Fail |
| Share count didn't rise | Fail | Fail | Pass |
| Gross margin rose | — | Pass | Fail |
| Revenue rose relative to assets | — | — | Fail |
| F-score | — | — | 2 of 9 |
Compare
Put Telix Pharmaceuticals side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Telix Pharmaceuticals | FY25 | 55.6% | 3.7% | −5.3% | 5.0% | 5.1x | 2 | |
| Collegium Pharmaceutical | FY25 | 23.6% | 23.0% | 42.0% | 53.4% | −0.4x | 6 | Compare |
| Corcept Therapeutics | FY25 | 12.8% | 5.9% | 18.6% | 15.7% | −8.1x | 3 | Compare |
| Emergent BioSolutions | FY25 | −28.8% | 13.5% | 21.1% | 6.4% | 2.0x | 7 | Compare |
| ANI Pharmaceuticals | FY25 | 43.8% | 12.6% | 19.4% | 15.9% | 0.1x | 6 | Compare |
4 years of figures
| Fiscal year | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | — | 333 | 517 | 804 |
| Revenue growth | — | — | 55.1% | 55.6% |
| Gross profit | — | 210 | 336 | 426 |
| Research and development | — | 85 | 128 | 171 |
| Operating income | — | 11 | 55 | 30 |
| Net income | — | 4 | 34 | −7 |
| Diluted EPS (US$) | — | 0.01 | 0.10 | −0.02 |
| Diluted shares (millions) | 311 | 324 | 345 | 338 |
| Cash flow | ||||
| Cash from operations | — | 14 | 28 | −17 |
| Capital expenditure | — | 6 | 9 | 26 |
| Free cash flow | — | 8 | 18 | −43 |
| Dividends paid | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 21 | 221 |
| Stock-based compensation | — | 6 | 13 | 19 |
| Balance sheet at fiscal year end | ||||
| Cash and short-term investments | 79 | 84 | 440 | 142 |
| Debt incl. finance leases | — | 7 | 354 | 405 |
| Total assets | — | 277 | 940 | 1,164 |
| Total liabilities | — | 175 | 587 | 749 |
| Shareholders' equity | 55 | 103 | 353 | 415 |
| Margins and ratios | ||||
| Gross margin | — | 62.9% | 65.1% | 53.0% |
| Operating margin | — | 3.3% | 10.7% | 3.7% |
| Net margin | — | 1.3% | 6.5% | −0.9% |
| Free cash flow margin | — | 2.4% | 3.6% | −5.3% |
| Rule of 40 (growth + FCF margin) | — | — | 58.7% | 50.3% |
| Return on capital | — | — | 33.6% | 5.0% |
| Return on equity | — | — | 14.8% | −1.9% |
| Return on assets | — | — | 5.5% | −0.7% |
| Net debt to EBITDA | — | −5.0x | −1.4x | 5.1x |